Insulet reports ‘positive’ results from Omnipod 5 trial

Insulet presented positive results from its first randomized controlled trial showing improved glycemic and patient-reported outcomes in type 1 diabetes with the Omnipod 5 Automated Insulin Delivery System. The OP5-003 Trial results were presented at the 17th International Conference on Advanced Technologies & Treatments for Diabetes in Florence, Italy. Professor Eric Renard, MD, PhD of Montpellier University Hospital, shared evidence of the efficacy and safety of the automated Omnipod 5 System compared to insulin pump therapy with continuous glucose monitoring in adults with type 1 diabetes in the United States and France. Omnipod 5 use led to a 17.5% improvement in time in range, decreased HbA1c, decreased percentage of time in hypoglycemia, and decreased mean glucose in individuals with baseline HbA1c levels above the recommended target. “Omnipod 5 continues to demonstrate impressive clinical outcomes for people with type 1 diabetes,” said Professor Renard. “We expect this latest set of compelling evidence to have a profound impact on international accessibility and affordability, allowing more people with diabetes to experience the benefits provided by this innovative technology.”